Merck & Co.’s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company’s revenue, is raising investor concerns as the drug’s patent expiration approaches in 2028, The Wall Street Journal reported Feb. 5.
Category: Featured
GLP-1 drug fails to slow Parkinson's: Study
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson’s disease.
Oregon bill would ban AI nurses
An Oregon state representative has introduced a bill that would outlaw AI nurses.
UK HealthCare to spend $95M on Epic, Workday
Lexington, Ky.-based UK HealthCare has allocated $95 million for upcoming Epic and Workday software rollouts, Morehead (Ky.) State Public Radio reported.
'A gap in the literature': Why Ascension aims to diversify telehealth
St. Louis-based Ascension aims to make telehealth more equitable when identifying pressure injuries remotely.
New Jersey introduces bill to ban anesthesia time limits
State lawmakers in New Jersey have introduced a bill to ban payers from placing time limits on anesthesia services.
Memorial Hermann breaks ground in next phase of $231M project
Memorial Hermann Sugar Land (Texas) Hospital broke ground Feb. 3 on its north tower, the next phase in a $231 million expansion project that kicked off in 2022.
The burden of anesthesia on-call demands: 5 stats to know
Anesthesiologists are on call an average of 58 days per year, according to a report from Physician Side Gigs, an online community of more than 195,000 physicians.
What's driving private practice patient acquisition costs?
It can cost physician practices anywhere between $155 to $582 to acquire a new patient, according to a recent survey from healthcare software company Tebra published Jan. 30.
Kaiser Permanente's leadership shakeup: 3 move to know
Oakland, Calif.-based Kaiser Permanente has made three major leadership moves since Jan. 1:
